Post-translational Regulation of GLT-1 in Neurological Diseases and Its Potential as an Effective Therapeutic Target

被引:45
|
作者
Peterson, Allison R. [1 ]
Binder, Devin K. [1 ]
机构
[1] Univ Calif Riverside, Div Biomed Sci, Sch Med, Ctr Glial Neuronal Interact, Riverside, CA 92521 USA
来源
关键词
GLT-1; palmitoylation; S-nitrosylation; sumoylation; ubiquitination; post-translational modifications; GLUTAMATE TRANSPORTER GLT-1; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; MOUSE MODEL; ALZHEIMERS-DISEASE; S-NITROSYLATION; UP-REGULATION; CELL-DEATH; EXPRESSION; CEFTRIAXONE;
D O I
10.3389/fnmol.2019.00164
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Glutamate transporter-1 (GLT-1) is a Na+-dependent transporter that plays a key role in glutamate homeostasis by removing excess glutamate in the central nervous system (CNS). GLT-1 dysregulation occurs in various neurological diseases including Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and epilepsy. Downregulation or dysfunction of GLT-1 has been a common finding across these diseases but how this occurs is still under investigation. This review aims to highlight post-translational regulation of GLT-1 which leads to its downregulation including sumoylation, palmitoylation, nitrosylation, ubiquitination, and subcellular localization. Various therapeutic interventions to restore GLT-1, their proposed mechanism of action and functional effects will be examined as potential treatments to attenuate the neurological symptoms associated with loss or downregulation of GLT-1.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] GLT-1 transporter: An effective pharmacological target for various neurological disorders
    Soni, Neha
    Reddy, B. V. K.
    Kumar, Puneet
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2014, 127 : 70 - 81
  • [2] GLT-1 Upregulation as a Potential Therapeutic Target for Ischemic Brain Injury
    Hu, Yu-Yan
    Li, Li
    Xian, Xiao-Hui
    Zhang, Min
    Sun, Xiao-Cai
    Li, Shu-Qin
    Cui, Xin
    Qi, Jie
    Li, Wen-Bin
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (33) : 5045 - 5055
  • [3] Post-Translational Modifications of STING: A Potential Therapeutic Target
    Kang, Jiaqi
    Wu, Jie
    Liu, Qinjie
    Wu, Xiuwen
    Zhao, Yun
    Ren, Jianan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] EXPLORATION OF GLUTAMATE TRANSPORTER-1 (GLT-1) AS A POTENTIAL THERAPEUTIC TARGET FOR NEUROPROTECTION
    Verma, R.
    Mishra, V
    Sasmal, D.
    Raghubir, R.
    JOURNAL OF NEUROCHEMISTRY, 2010, 115 : 70 - 70
  • [5] Glutamate transporter-1 (GLT-1): a potential therapeutic target for the treatment of central nervous system diseases and disorders
    Abou-Gharbia, M.
    Blass, B.
    Childers, W.
    Ramanjulu, M.
    Melenski, E.
    DRUGS OF THE FUTURE, 2017, 42 (08) : 489 - 509
  • [6] Post-translational modification of the death receptor complex as a potential therapeutic target in cancer
    Kidong Kang
    So-Ra Lee
    Xuezhe Piao
    Gang Min Hur
    Archives of Pharmacal Research, 2019, 42 : 76 - 87
  • [7] Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
    Roberts-Wolfe, Douglas J.
    Kalivas, Peter W.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2015, 14 (06) : 745 - 756
  • [8] Post-translational modification of the death receptor complex as a potential therapeutic target in cancer
    Kang, Kidong
    Lee, So-Ra
    Piao, Xuezhe
    Hur, Gang Min
    ARCHIVES OF PHARMACAL RESEARCH, 2019, 42 (01) : 76 - 87
  • [9] SUMO - a post-translational modification with therapeutic potential?
    Woo, Chang-Hoon
    Abe, Jun-ichi
    CURRENT OPINION IN PHARMACOLOGY, 2010, 10 (02) : 146 - 155
  • [10] Astrocyte glutamate transporter GLT-1 as a possible therapeutic target in Rett syndrome
    Albizzati, E.
    Taiarol, L.
    Frasca, A.
    Landsberger, N.
    GLIA, 2019, 67 : E384 - E385